{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:17:32Z","timestamp":1781133452457,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.7759\/cureus.67070","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T14:07:48Z","timestamp":1723903668000},"source":"Crossref","is-referenced-by-count":2,"title":["Correlation Between Hemoglobin A1c (HbA1c) and High-Sensitivity C-Reactive Protein (hs-CRP) in Myocardial Infarction Patients and Their Six-Month Mortality Follow-Up"],"prefix":"10.7759","author":[{"given":"Keesari Sai Sandeep","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini","family":"Varadaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunasekaran","family":"Nallusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbiah","family":"SenthilNathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016, 388:1545-602. 10.1016\/S0140-6736(16)31678-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.05.029","article-title":"Prevalence and impact of metabolic syndrome in patients with multivessel coronary artery disease and acute coronary syndrome","volume":"31","author":"Zhou J","year":"2021","unstructured":"Zhou J, Liu C, Zhou P, et al.. Prevalence and impact of metabolic syndrome in patients with multivessel coronary artery disease and acute coronary syndrome. Nutr Metab Cardiovasc Dis. 2021, 31:2693-9. 10.1016\/j.numecd.2021.05.029","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy SM","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, et al.. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005, 112:2735-52. 10.1161\/CIRCULATIONAHA.105.169404","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000053731.05365.5a","article-title":"Coming of age of C-reactive protein: using inflammation markers in cardiology","volume":"107","author":"Yeh ET","year":"2003","unstructured":"Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003, 107:370-1. 10.1161\/01.cir.0000053731.05365.5a","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/47.3.403","article-title":"High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease","volume":"47","author":"Rifai N","year":"2001","unstructured":"Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001, 47:403-11.","journal-title":"Clin Chem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-2-49","article-title":"Impact of hyperglycemia on morbidity and mortality, length of hospitalization and rates of re-hospitalization in a general hospital setting in Brazil","volume":"2","author":"Leite SA","year":"2010","unstructured":"Leite SA, Locatelli SB, Niece SP, Oliveira AR, Tockus D, Tosin T. Impact of hyperglycemia on morbidity and mortality, length of hospitalization and rates of re-hospitalization in a general hospital setting in Brazil. Diabetol Metab Syndr. 2010, 2:49. 10.1186\/1758-5996-2-49","journal-title":"Diabetol Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.99.20.2626","article-title":"Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study","volume":"99","author":"Malmberg K","year":"1999","unstructured":"Malmberg K, Norhammar A, Wedel H, Ryd\u00e9n L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. 1999, 99:2626-32. 10.1161\/01.cir.99.20.2626","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan AD","year":"2018","unstructured":"Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. 2018, 138:141-9. 10.1161\/CIRCULATIONAHA.118.034645","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee M","year":"2001","unstructured":"Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414:813-20. 10.1038\/414813a","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker PM","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016, 118:145-56. 10.1161\/CIRCRESAHA.115.306656","journal-title":"Circ Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett BM","year":"2018","unstructured":"Everett BM, Donath MY, Pradhan AD, et al.. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018, 71:2392-401. 10.1016\/j.jacc.2018.03.002","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker PM","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018, 391:319-28. 10.1016\/S0140-6736(17)32814-3","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.29","article-title":"Insulin resistance and hyperglycaemia in cardiovascular disease development","volume":"10","author":"Laakso M","year":"2014","unstructured":"Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014, 10:293-302. 10.1038\/nrendo.2014.29","journal-title":"Nat Rev Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede P","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358:580-91. 10.1056\/NEJMoa0706245","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/284364-correlation-between-hemoglobin-a1c-hba1c-and-high-sensitivity-c-reactive-protein-hs-crp-in-myocardial-infarction-patients-and-their-six-month-mortality-follow-up","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T14:07:53Z","timestamp":1723903673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/284364-correlation-between-hemoglobin-a1c-hba1c-and-high-sensitivity-c-reactive-protein-hs-crp-in-myocardial-infarction-patients-and-their-six-month-mortality-follow-up"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.67070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}